CA3175130A1 - Treatment with powdered intranasal epinephrine - Google Patents
Treatment with powdered intranasal epinephrineInfo
- Publication number
- CA3175130A1 CA3175130A1 CA3175130A CA3175130A CA3175130A1 CA 3175130 A1 CA3175130 A1 CA 3175130A1 CA 3175130 A CA3175130 A CA 3175130A CA 3175130 A CA3175130 A CA 3175130A CA 3175130 A1 CA3175130 A1 CA 3175130A1
- Authority
- CA
- Canada
- Prior art keywords
- epinephrine
- pharmaceutical composition
- particles
- dose
- type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062989913P | 2020-03-16 | 2020-03-16 | |
| US62/989,913 | 2020-03-16 | ||
| US17/135,528 US11400045B2 (en) | 2020-03-16 | 2020-12-28 | Treatment with powdered intranasal epinephrine |
| US17/135,528 | 2020-12-28 | ||
| PCT/IL2021/050288 WO2021186437A1 (en) | 2020-03-16 | 2021-03-16 | Treatment with powdered intranasal epinephrine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3175130A1 true CA3175130A1 (en) | 2021-09-23 |
Family
ID=77664091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3175130A Pending CA3175130A1 (en) | 2020-03-16 | 2021-03-16 | Treatment with powdered intranasal epinephrine |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11400045B2 (https=) |
| EP (1) | EP4121005A1 (https=) |
| JP (1) | JP2023517532A (https=) |
| KR (1) | KR20220154709A (https=) |
| CN (1) | CN115279340A (https=) |
| AR (1) | AR121593A1 (https=) |
| AU (1) | AU2021239084A1 (https=) |
| BR (1) | BR112022018440A2 (https=) |
| CA (1) | CA3175130A1 (https=) |
| IL (1) | IL296268A (https=) |
| MX (1) | MX2022011464A (https=) |
| TW (1) | TW202200119A (https=) |
| WO (1) | WO2021186437A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11400045B2 (en) * | 2020-03-16 | 2022-08-02 | Nasus Pharma Ltd. | Treatment with powdered intranasal epinephrine |
| PT3962455T (pt) | 2020-05-18 | 2022-10-13 | Orexo Ab | Nova composição farmacêutica para entrega de fármacos |
| US12414916B2 (en) | 2021-06-10 | 2025-09-16 | Belhaven BioPharma Inc. | Dry powder formulations of epinephrine and associated methods |
| AR127780A1 (es) | 2021-11-25 | 2024-02-28 | Orexo Ab | Nueva composición farmacéutica que comprende adrenalina |
| GB202117016D0 (en) | 2021-11-25 | 2022-01-12 | Orexo Ab | New pharmaceutical device |
| US12029709B2 (en) | 2022-08-11 | 2024-07-09 | De Motu Cordis Pty Ltd | Inhalable epinephrine formulation |
| KR20250048076A (ko) * | 2022-08-11 | 2025-04-07 | 드 모투 코르디스 피티와이 엘티디 | 흡입형 에피네프린 제형 |
| TW202502309A (zh) * | 2023-05-31 | 2025-01-16 | 瑞典商奥瑞克索股份公司 | 包含腎上腺素激導性受體調節劑的噴霧乾燥之組合物 |
| US20260108686A1 (en) | 2024-10-21 | 2026-04-23 | Belhaven BioPharma Inc. | Compositions, devices, and methods for intranasal delivery of dry powder epinephrine |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8337817B2 (en) * | 2006-12-26 | 2012-12-25 | Shin Nippon Biomedical Laboratories, Ltd. | Preparation for transnasal application |
| CN102166219B (zh) * | 2010-05-25 | 2013-04-17 | 杭州天龙药业有限公司 | 一种鼻腔给药制剂及其应用 |
| US9789071B2 (en) | 2012-06-27 | 2017-10-17 | G2B Pharma, Inc. | Intranasal formulation of epinephrine for the treatment of anaphylaxis |
| MX2016002705A (es) | 2013-09-03 | 2016-09-06 | G2B Pharma Inc | Formulacion intranasal para el tratamiento por reanimacion cardiopulmonar (rcp), mantenimiento cardiaco vital (cls), de anafilaxia y/o reacciones anafilactoides. |
| US20200069582A1 (en) | 2014-07-03 | 2020-03-05 | Darren Rubin | Inhalable hemodynamic agents and methods of using the same |
| CN107205938A (zh) * | 2014-12-18 | 2017-09-26 | 温德加普医疗股份有限公司 | 用于溶解或增溶治疗剂的方法和组合物 |
| US11844859B2 (en) * | 2017-08-20 | 2023-12-19 | Nasus Pharma Ltd. | Dry powder compositions for intranasal delivery |
| EP3668490A4 (en) * | 2017-08-20 | 2021-06-09 | Formulex Pharma Innovations Ltd. | Dry powder compositions for intranasal delivery |
| GB2600026B (en) * | 2018-02-06 | 2022-10-12 | Aegis Therapeutics Llc | Intranasal epinephrine formulations and methods for the treatment of disease |
| US11400045B2 (en) * | 2020-03-16 | 2022-08-02 | Nasus Pharma Ltd. | Treatment with powdered intranasal epinephrine |
-
2020
- 2020-12-28 US US17/135,528 patent/US11400045B2/en active Active
-
2021
- 2021-03-16 MX MX2022011464A patent/MX2022011464A/es unknown
- 2021-03-16 JP JP2022552858A patent/JP2023517532A/ja active Pending
- 2021-03-16 EP EP21714436.9A patent/EP4121005A1/en active Pending
- 2021-03-16 CA CA3175130A patent/CA3175130A1/en active Pending
- 2021-03-16 WO PCT/IL2021/050288 patent/WO2021186437A1/en not_active Ceased
- 2021-03-16 BR BR112022018440A patent/BR112022018440A2/pt unknown
- 2021-03-16 AR ARP210100664A patent/AR121593A1/es unknown
- 2021-03-16 KR KR1020227033697A patent/KR20220154709A/ko not_active Withdrawn
- 2021-03-16 CN CN202180020993.7A patent/CN115279340A/zh active Pending
- 2021-03-16 AU AU2021239084A patent/AU2021239084A1/en active Pending
- 2021-03-16 IL IL296268A patent/IL296268A/en unknown
- 2021-03-16 US US17/911,523 patent/US20230105615A1/en active Pending
- 2021-03-16 TW TW110109439A patent/TW202200119A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4121005A1 (en) | 2023-01-25 |
| TW202200119A (zh) | 2022-01-01 |
| WO2021186437A1 (en) | 2021-09-23 |
| KR20220154709A (ko) | 2022-11-22 |
| BR112022018440A2 (pt) | 2022-11-01 |
| MX2022011464A (es) | 2022-11-14 |
| US20210283050A1 (en) | 2021-09-16 |
| US11400045B2 (en) | 2022-08-02 |
| IL296268A (en) | 2022-11-01 |
| US20230105615A1 (en) | 2023-04-06 |
| AR121593A1 (es) | 2022-06-22 |
| CN115279340A (zh) | 2022-11-01 |
| JP2023517532A (ja) | 2023-04-26 |
| AU2021239084A1 (en) | 2022-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11400045B2 (en) | Treatment with powdered intranasal epinephrine | |
| JP7621220B2 (ja) | 疾患の処置のための鼻腔内エピネフリン製剤及び方法 | |
| CN110996912A (zh) | 用于鼻内递送的干粉组合物 | |
| US12303472B2 (en) | Pharmaceutical device for use in intranasal administration | |
| CA2962531C (en) | Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation | |
| US20240358650A1 (en) | Inhalable hormone receptor agonist formulations | |
| KR102375232B1 (ko) | 비강내 에피네프린 제제 및 질환의 치료 방법 | |
| US20140377365A1 (en) | Sustained-release formulation of rotigotine | |
| AU2015338717B2 (en) | Powder formulation | |
| KR19990021931A (ko) | 미세구형 전분의 항편두통 조성물 | |
| CN107847482A (zh) | 喷雾器用组合物 | |
| HK40092206A (zh) | 鼻内肾上腺素制剂及治疗疾病的方法 | |
| HK40018410B (en) | Intranasal epinephrine formulations and methods for the treatment of disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250307 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250307 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250324 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250325 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250325 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250325 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250430 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250512 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250612 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251030 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260303 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260303 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260422 |